O	0	11	Therapeutic	Therapeutic	JJ	B-NP
O	12	24	angiogenesis	angiogenesis	NN	I-NP
O	24	25	:	:	:	O
O	26	27	a	a	DT	B-NP
O	28	35	complex	complex	JJ	I-NP
O	36	43	problem	problem	NN	I-NP
O	44	53	requiring	require	VBG	B-VP
O	54	55	a	a	DT	B-NP
O	56	69	sophisticated	sophisticated	JJ	I-NP
O	70	78	approach	approach	NN	I-NP
O	78	79	.	.	.	O

B-Organism_substance	80	85	Blood	Blood	NN	B-NP
O	86	89	and	and	CC	O
B-Multi-tissue_structure	90	98	vascular	vascular	JJ	B-NP
O	99	108	disorders	disorder	NNS	I-NP
O	109	117	underlie	underlie	VBP	B-VP
O	118	119	a	a	DT	B-NP
O	120	128	plethora	plethora	NN	I-NP
O	129	131	of	of	IN	B-PP
O	132	142	pathologic	pathologic	JJ	B-NP
O	143	153	conditions	condition	NNS	I-NP
O	154	157	and	and	CC	O
O	158	161	are	be	VBP	B-VP
O	162	165	the	the	DT	B-NP
O	166	172	single	single	JJ	I-NP
O	173	177	most	most	RBS	I-NP
O	178	186	frequent	frequent	JJ	I-NP
O	187	192	cause	cause	NN	I-NP
O	193	195	of	of	IN	B-PP
O	196	201	human	human	JJ	B-NP
O	202	209	disease	disease	NN	I-NP
O	209	210	.	.	.	O

O	211	219	Ischemia	Ischemia	NNP	B-NP
O	219	220	,	,	,	O
O	221	230	involving	involve	VBG	B-VP
O	231	241	restricted	restricted	JJ	B-NP
B-Organism_substance	242	247	blood	blood	NN	I-NP
O	248	252	flow	flow	NN	I-NP
O	253	255	to	to	TO	B-PP
B-Tissue	256	263	tissues	tissue	NNS	B-NP
O	264	266	is	be	VBZ	B-VP
O	267	270	the	the	DT	B-NP
O	271	275	most	most	RBS	I-NP
O	276	282	common	common	JJ	I-NP
O	283	294	consequence	consequence	NN	I-NP
O	295	297	of	of	IN	B-PP
B-Multi-tissue_structure	298	304	vessel	vessel	NN	B-NP
O	305	316	dysfunction	dysfunction	NN	I-NP
O	317	326	resulting	result	VBG	B-VP
O	327	329	in	in	IN	B-PP
O	330	333	the	the	DT	B-NP
O	334	344	disruption	disruption	NN	I-NP
O	345	347	of	of	IN	B-PP
O	348	354	oxygen	oxygen	NN	B-NP
O	355	358	and	and	CC	I-NP
O	359	367	nutrient	nutrient	NN	I-NP
O	368	376	delivery	delivery	NN	I-NP
O	377	380	and	and	CC	O
O	381	384	the	the	DT	B-NP
O	385	397	accumulation	accumulation	NN	I-NP
O	398	400	of	of	IN	B-PP
O	401	406	waste	waste	NN	B-NP
O	407	418	metabolites	metabolite	NNS	I-NP
O	418	419	.	.	.	O

B-Cell	420	425	Cells	Cell	NNS	B-NP
O	426	432	cannot	cannot	MD	B-VP
O	433	440	survive	survive	VB	I-VP
O	441	449	extended	extended	JJ	B-NP
O	450	456	severe	severe	JJ	I-NP
O	457	465	ischemia	ischemia	NN	I-NP
O	466	469	but	but	CC	O
O	470	473	may	may	MD	B-VP
O	474	476	be	be	VB	I-VP
O	477	481	able	able	JJ	B-ADJP
O	482	484	to	to	TO	B-VP
O	485	490	adapt	adapt	VB	I-VP
O	491	493	to	to	TO	B-PP
O	494	495	a	a	DT	B-NP
O	496	504	moderate	moderate	JJ	I-NP
O	505	514	condition	condition	NN	I-NP
O	515	520	where	where	WRB	B-ADVP
O	521	530	diffusion	diffusion	NN	B-NP
O	531	533	to	to	TO	B-PP
O	534	537	and	and	CC	I-PP
O	538	542	from	from	IN	I-PP
O	543	552	bordering	border	VBG	B-VP
O	553	564	nonischemic	nonischemic	JJ	B-NP
O	565	572	regions	region	NNS	I-NP
O	573	581	sustains	sustain	VBZ	B-VP
O	582	587	vital	vital	JJ	B-NP
O	588	597	functions	function	NNS	I-NP
O	597	598	.	.	.	O

O	599	604	Under	Under	IN	B-PP
O	605	609	this	this	DT	B-NP
O	610	619	condition	condition	NN	I-NP
O	619	620	,	,	,	O
O	621	624	the	the	DT	B-NP
O	625	634	secondary	secondary	JJ	I-NP
O	635	644	functions	function	NNS	I-NP
O	645	647	of	of	IN	B-PP
O	648	656	effected	effect	VBN	B-NP
B-Cell	657	662	cells	cell	NNS	I-NP
O	663	666	are	be	VBP	B-VP
O	667	673	likely	likely	JJ	B-ADJP
O	674	676	to	to	TO	B-VP
O	677	679	be	be	VB	I-VP
O	680	688	impaired	impair	VBN	I-VP
O	688	689	,	,	,	O
O	690	693	and	and	CC	O
O	694	695	a	a	DT	B-NP
O	696	699	new	new	JJ	I-NP
O	700	709	metabolic	metabolic	JJ	I-NP
O	710	721	equilibrium	equilibrium	NN	I-NP
O	722	724	is	be	VBZ	B-VP
O	725	736	established	establish	VBN	I-VP
O	736	737	,	,	,	O
O	738	748	determined	determine	VBN	B-VP
O	749	751	by	by	IN	B-PP
O	752	755	the	the	DT	B-NP
O	756	761	level	level	NN	I-NP
O	762	764	of	of	IN	B-PP
O	765	770	cross	cross	AFX	B-NP
O	770	771	-	-	HYPH	I-NP
O	771	780	diffusion	diffusion	NN	I-NP
O	781	784	and	and	CC	I-NP
O	785	791	degree	degree	NN	I-NP
O	792	794	of	of	IN	B-PP
O	795	802	hypoxia	hypoxia	NN	B-NP
O	802	803	.	.	.	O

O	804	806	In	In	IN	B-PP
B-Tissue	807	814	tissues	tissue	NNS	B-NP
O	815	819	with	with	IN	B-PP
O	820	821	a	a	DT	B-NP
O	822	830	normally	normally	RB	I-NP
O	831	835	high	high	JJ	I-NP
O	836	845	metabolic	metabolic	JJ	I-NP
O	846	854	turnover	turnover	NN	I-NP
O	855	859	such	such	JJ	B-PP
O	860	862	as	as	IN	I-PP
B-Tissue	863	871	skeletal	skeletal	JJ	B-NP
O	872	875	and	and	CC	I-NP
B-Tissue	876	883	cardiac	cardiac	JJ	I-NP
I-Tissue	884	890	muscle	muscle	NN	I-NP
O	890	891	,	,	,	O
O	892	896	even	even	RB	B-NP
O	897	901	mild	mild	JJ	I-NP
O	902	910	ischemia	ischemia	NN	I-NP
O	911	917	causes	cause	VBZ	B-VP
O	918	925	hypoxia	hypoxia	NN	B-NP
O	925	926	,	,	,	O
O	927	935	acidosis	acidosis	NN	B-NP
O	935	936	,	,	,	O
O	937	940	and	and	CC	O
O	941	950	depressed	depress	VBN	B-VP
O	951	959	function	function	NN	B-NP
O	960	961	(	(	(	O
O	961	974	contractility	contractility	NN	B-NP
O	974	975	)	)	)	O
O	976	979	and	and	CC	O
O	980	990	eventually	eventually	RB	B-VP
O	991	1000	threatens	threaten	VBZ	I-VP
B-Cell	1001	1008	myocyte	myocyte	NN	B-NP
O	1009	1018	viability	viability	NN	I-NP
O	1019	1022	and	and	CC	O
B-Organ	1023	1028	organ	organ	NN	B-NP
O	1029	1037	function	function	NN	I-NP
O	1037	1038	.	.	.	O

O	1039	1047	Ischemic	Ischemic	JJ	B-NP
B-Tissue	1048	1055	cardiac	cardiac	JJ	I-NP
I-Tissue	1056	1062	muscle	muscle	NN	I-NP
O	1063	1065	is	be	VBZ	B-VP
O	1066	1078	additionally	additionally	RB	B-ADJP
O	1079	1089	vulnerable	vulnerable	JJ	I-ADJP
O	1090	1097	because	because	IN	B-SBAR
O	1098	1109	reperfusion	reperfusion	NN	B-NP
O	1110	1112	is	be	VBZ	B-VP
O	1113	1122	essential	essential	JJ	B-ADJP
O	1123	1126	for	for	IN	B-PP
O	1127	1135	survival	survival	NN	B-NP
O	1136	1139	but	but	CC	O
O	1140	1151	reperfusion	reperfusion	NN	B-NP
O	1152	1158	itself	itself	PRP	B-NP
O	1159	1164	poses	pose	VBZ	B-VP
O	1165	1175	additional	additional	JJ	B-NP
O	1176	1182	stress	stress	NN	I-NP
O	1183	1194	principally	principally	RB	B-ADVP
O	1195	1199	from	from	IN	B-PP
O	1200	1209	increased	increase	VBN	B-NP
O	1210	1220	production	production	NN	I-NP
O	1221	1223	of	of	IN	B-PP
O	1224	1228	free	free	JJ	B-NP
O	1229	1237	radicals	radical	NNS	I-NP
O	1238	1244	during	during	IN	B-PP
O	1245	1258	reoxygenation	reoxygenation	NN	B-NP
O	1258	1259	.	.	.	O

O	1260	1263	The	The	DT	B-NP
O	1264	1270	latter	latter	JJ	I-NP
O	1271	1277	effect	effect	NN	I-NP
O	1278	1280	is	be	VBZ	B-VP
O	1281	1287	called	call	VBN	I-VP
O	1288	1299	reperfusion	reperfusion	NN	B-NP
O	1300	1306	injury	injury	NN	I-NP
O	1307	1310	and	and	CC	O
O	1311	1314	can	can	MD	B-VP
O	1315	1320	cause	cause	VB	I-VP
O	1321	1323	as	as	IN	B-NP
O	1324	1328	much	much	JJ	I-NP
O	1329	1335	damage	damage	NN	I-NP
O	1336	1338	as	as	IN	B-PP
O	1339	1342	the	the	DT	B-NP
O	1343	1351	ischemia	ischemia	NN	I-NP
O	1351	1352	.	.	.	O

O	1353	1356	The	The	DT	B-NP
O	1357	1366	treatment	treatment	NN	I-NP
O	1367	1380	possibilities	possibility	NNS	I-NP
O	1381	1384	for	for	IN	B-PP
O	1385	1393	ischemia	ischemia	NN	B-NP
O	1393	1394	-	-	HYPH	O
O	1394	1401	related	relate	VBN	B-NP
B-Multi-tissue_structure	1402	1410	vascular	vascular	JJ	I-NP
O	1411	1418	disease	disease	NN	I-NP
O	1419	1422	are	be	VBP	B-VP
O	1423	1430	limited	limit	VBN	B-ADJP
O	1430	1431	.	.	.	O

O	1432	1437	Lipid	Lipid	NN	B-NP
O	1437	1438	/	/	SYM	I-NP
O	1438	1449	cholesterol	cholesterol	NN	I-NP
O	1449	1450	-	-	HYPH	B-VP
O	1450	1458	lowering	lower	VBG	B-NP
O	1459	1465	agents	agent	NNS	I-NP
O	1465	1466	,	,	,	O
O	1467	1471	diet	diet	NN	B-NP
O	1472	1475	and	and	CC	O
B-Cell	1476	1488	antiplatelet	antiplatelet	JJ	B-NP
O	1489	1498	adherence	adherence	NN	I-NP
O	1499	1500	(	(	(	O
O	1500	1507	aspirin	aspirin	NN	B-NP
O	1507	1508	)	)	)	O
O	1509	1516	therapy	therapy	NN	B-NP
O	1517	1520	may	may	MD	B-VP
O	1521	1525	help	help	VB	I-VP
O	1526	1530	slow	slow	VB	I-VP
O	1531	1534	the	the	DT	B-NP
O	1535	1546	progression	progression	NN	I-NP
O	1547	1549	of	of	IN	B-PP
B-Multi-tissue_structure	1550	1556	vessel	vessel	NN	B-NP
O	1557	1564	disease	disease	NN	I-NP
O	1565	1567	in	in	IN	B-PP
O	1568	1572	some	some	DT	B-NP
O	1573	1582	instances	instance	NNS	I-NP
O	1582	1583	;	;	:	O
O	1584	1587	but	but	CC	O
O	1588	1596	surgical	surgical	JJ	B-NP
O	1597	1611	reconstruction	reconstruction	NN	I-NP
O	1612	1615	may	may	MD	B-VP
O	1616	1618	be	be	VB	I-VP
O	1619	1622	the	the	DT	B-NP
O	1623	1627	only	only	JJ	I-NP
O	1628	1634	option	option	NN	I-NP
O	1635	1637	in	in	IN	B-PP
O	1638	1646	advanced	advance	VBN	B-NP
O	1647	1653	stages	stage	NNS	I-NP
O	1653	1654	,	,	,	O
O	1655	1658	and	and	CC	O
O	1659	1663	even	even	RB	B-ADVP
O	1664	1668	this	this	DT	B-NP
O	1669	1671	is	be	VBZ	B-VP
O	1672	1675	not	not	RB	O
O	1676	1682	always	always	RB	B-ADVP
O	1683	1685	an	an	DT	B-NP
O	1686	1692	option	option	NN	I-NP
O	1692	1693	.	.	.	O

O	1694	1696	An	An	DT	B-NP
O	1697	1708	alternative	alternative	JJ	I-NP
O	1709	1712	and	and	CC	I-NP
O	1713	1719	rather	rather	RB	I-NP
O	1720	1727	obvious	obvious	JJ	I-NP
O	1728	1736	strategy	strategy	NN	I-NP
O	1737	1739	to	to	TO	B-VP
O	1740	1745	treat	treat	VB	I-VP
O	1746	1754	ischemia	ischemia	NN	B-NP
O	1755	1757	is	be	VBZ	B-VP
O	1758	1760	to	to	TO	B-VP
O	1761	1769	activate	activate	VB	I-VP
O	1770	1780	endogenous	endogenous	JJ	B-NP
O	1781	1791	angiogenic	angiogenic	JJ	I-NP
O	1792	1794	or	or	CC	I-NP
O	1795	1807	arteriogenic	arteriogenic	JJ	I-NP
O	1808	1816	pathways	pathway	NNS	I-NP
O	1817	1819	to	to	TO	B-VP
O	1820	1829	stimulate	stimulate	VB	I-VP
O	1830	1847	revascularization	revascularization	NN	B-NP
O	1848	1850	of	of	IN	B-PP
O	1851	1854	the	the	DT	B-NP
B-Tissue	1855	1861	tissue	tissue	NN	I-NP
O	1861	1862	.	.	.	O

O	1863	1866	The	The	DT	B-NP
O	1867	1878	feasibility	feasibility	NN	I-NP
O	1879	1881	of	of	IN	B-PP
O	1882	1886	such	such	JJ	B-NP
O	1887	1888	a	a	DT	I-NP
O	1889	1897	strategy	strategy	NN	I-NP
O	1898	1901	has	have	VBZ	B-VP
O	1902	1905	now	now	RB	I-VP
O	1906	1910	been	be	VBN	I-VP
O	1911	1922	established	establish	VBN	I-VP
O	1923	1930	through	through	IN	B-PP
O	1931	1934	the	the	DT	B-NP
O	1935	1942	results	result	NNS	I-NP
O	1943	1945	of	of	IN	B-PP
O	1946	1953	studies	study	NNS	B-NP
O	1954	1958	over	over	IN	B-PP
O	1959	1962	the	the	DT	B-NP
O	1963	1967	past	past	JJ	I-NP
O	1968	1974	decade	decade	NN	I-NP
O	1974	1975	,	,	,	O
O	1976	1979	and	and	CC	O
O	1980	1981	a	a	DT	B-NP
O	1982	1985	new	new	JJ	I-NP
O	1986	1996	discipline	discipline	NN	I-NP
O	1997	2003	called	call	VBN	B-VP
O	2004	2015	therapeutic	therapeutic	JJ	B-NP
O	2016	2028	angiogenesis	angiogenesis	NN	I-NP
O	2029	2032	has	have	VBZ	B-VP
O	2033	2040	emerged	emerge	VBN	I-VP
O	2040	2041	.	.	.	O

O	2042	2046	This	This	DT	B-NP
O	2047	2053	review	review	NN	I-NP
O	2054	2061	focuses	focus	VBZ	B-VP
O	2062	2064	on	on	IN	B-PP
O	2065	2068	the	the	DT	B-NP
O	2069	2080	application	application	NN	I-NP
O	2081	2083	of	of	IN	B-PP
O	2084	2095	therapeutic	therapeutic	JJ	B-NP
O	2096	2108	angiogenesis	angiogenesis	NN	I-NP
O	2109	2112	for	for	IN	B-PP
O	2113	2121	treating	treat	VBG	B-VP
O	2122	2130	ischemic	ischemic	JJ	B-NP
B-Organ	2131	2137	muscle	muscle	NN	I-NP
O	2138	2145	disease	disease	NN	I-NP
O	2146	2149	and	and	CC	O
O	2150	2158	includes	include	VBZ	B-VP
O	2159	2160	a	a	DT	B-NP
O	2161	2169	critical	critical	JJ	I-NP
O	2170	2180	evaluation	evaluation	NN	I-NP
O	2181	2183	of	of	IN	B-PP
O	2184	2187	the	the	DT	B-NP
O	2188	2198	parameters	parameter	NNS	I-NP
O	2199	2202	and	and	CC	I-NP
O	2203	2214	limitations	limitation	NNS	I-NP
O	2215	2217	of	of	IN	B-PP
O	2218	2225	current	current	JJ	B-NP
O	2226	2236	procedures	procedure	NNS	I-NP
O	2236	2237	.	.	.	O

O	2238	2241	The	The	DT	B-NP
O	2242	2253	development	development	NN	I-NP
O	2254	2256	of	of	IN	B-PP
O	2257	2261	this	this	DT	B-NP
O	2262	2272	technology	technology	NN	I-NP
O	2273	2276	has	have	VBZ	B-VP
O	2277	2286	benefited	benefit	VBN	I-VP
O	2287	2291	from	from	IN	B-PP
O	2292	2295	its	its	PRP$	B-NP
O	2296	2307	application	application	NN	I-NP
O	2308	2310	to	to	TO	B-PP
O	2311	2315	both	both	CC	O
B-Tissue	2316	2326	peripheral	peripheral	JJ	B-NP
O	2327	2330	and	and	CC	I-NP
B-Multi-tissue_structure	2331	2339	coronary	coronary	JJ	I-NP
I-Multi-tissue_structure	2340	2346	artery	artery	NN	I-NP
O	2347	2354	disease	disease	NN	I-NP
O	2355	2358	and	and	CC	O
O	2359	2366	results	result	VBZ	B-VP
O	2367	2371	from	from	IN	B-PP
O	2372	2376	both	both	DT	B-NP
O	2377	2380	are	be	VBP	B-VP
O	2381	2389	reviewed	review	VBN	I-VP
O	2390	2394	here	here	RB	B-ADVP
O	2394	2395	.	.	.	O

